Series length used during trend analysis affects sensitivity to changes in progression rate in the Ocular Hypertension Treatment Study

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1252-1259

  Gardiner, Stuart K ^a   Demirel, Shaban ^a   de Moraes, Carlos Gustavo ^b,c   Liebmann, Jeffrey M ^b,c   Cioffi, George A ^d   Ritch, Robert ^b,e   Gordon, Mae O ^f   Kass, Michael A ^f  

^a DEVERS EYE INSTITUTE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Edward S Harkness Eye Institute   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL PROCEDURES; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TREND ANALYSIS; VISUAL SYSTEM PARAMETERS;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84874991002     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10218     Document Type: Article

References (14)

1. Gordon MO, Kass MA. for the Ocular Hypertension Treatment Study G. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573-583.
2. Kass M, Heuer D, Higginbotham E, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
3. Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2010;128:276-287.
4. The Advanced Glaucoma Intervention Study Group. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15:299-325.
5. Leske M, Heijl A, Hyman L, Bengtsson B. Early manifest glaucoma trial-design and baseline data. Ophthalmology. 1999;106:2144-2153.
6. Musch D, Lichter P, Guire K, Standardi C. Group TCS. The Collaborative Initial Glaucoma Treatment Study: study designs, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653-662.
7. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002;109: 1612-1621.
8. Caprioli J. The importance of rates in glaucoma. Amer J Ophthalmol. 2008;145:191-192.
9. Chauhan B, Garway-Heath D, Goni F, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008;92:569-573.
10. Demirel S, De Moraes CGV, Gardiner SK, et al. The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2012;53:224-227
11. De Moraes CG, Demirel S, Gardiner SK, et al. Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci. 2012;53:1704-1709.
12. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
13. Gardiner S, Demirel S, Johnson C. Perimetric indices as predictors of future glaucomatous functional change. Optom Vis Sci. 2011;88:56-62.
14. Gardiner S, Demirel S, Johnson C. Is there evidence for continued learning over multiple years in perimetry? Optom Vis Sci. 2008;85:1043-1048.